|
2026
|
P/S
|
Antivirals; Antibodies for medical purposes; Anticoagulants; Stem cells for medical purposes; Rad... |
|
|
P/S
|
Pharmaceutical and biological preparations for human use. |
|
|
P/S
|
Pharmaceutical and biological preparations for human use. |
|
|
P/S
|
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases,... |
|
2025
|
P/S
|
Pharmaceutical and biological preparations for human use. |
|
|
P/S
|
Pharmaceutical preparations for human use. |
|
|
P/S
|
Pharmaceutical preparations for human use. |
|
|
Invention
|
Therapy for the treatment of non-hodgkin lymphoma. Provided herein are methods of treating and/or... |
|
|
Invention
|
Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin... |
|
|
Invention
|
Pkc-theta modulators.
Disclosed are compounds, compositions and methods for treating disease, sy... |
|
|
Invention
|
Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carbo... |
|
|
Invention
|
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use.
Pr... |
|
|
Invention
|
Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl... |
|
|
Invention
|
Arnt degrading compounds and uses thereof.
Disclosed herein are ARNT degrading compounds, and us... |
|
|
Invention
|
Arnt degrading compounds and uses thereof. e.g.e.g., R1, R2, R3, R4, R5, R6, R7, R8, R9) are as d... |
|
|
Invention
|
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidi... |
|
|
Invention
|
Heterocyclic compounds and their use for treatment of helminthic infections and diseases.
Provid... |
|
|
Invention
|
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)pipe... |
|
|
Invention
|
Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morphol... |
|
2024
|
Invention
|
Therapy for the treatment of multiple myeloma. Provided herein are methods of treating and/or man... |
|
|
Invention
|
Antiproliferative compounds and second active agents for combined use.
Provided herein are metho... |
|
|
Invention
|
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-mor... |
|
|
Invention
|
Uses of anti-bcma chimeric antigen receptors.
Provided herein are uses of anti-B cell maturation... |
|
|
Invention
|
Combination therapies comprising apremilast and tyk2 inhibitors.
Provided herein are methods of ... |
|
|
Invention
|
Oral formulations of cytidine analogs and methods of use thereof.
The present disclosure provide... |
|
|
Invention
|
Cereblon binding compounds, compositions thereof, and methods of treatment therewith.
Provided h... |
|
|
Invention
|
Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of cli... |
|
|
Invention
|
Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use.
Provi... |
|
|
Invention
|
Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and com... |
|
|
Invention
|
Transgenic mouse expressing human cereblon.
Provided are transgenic mice whose genome comprises ... |
|
|
Invention
|
Compounds and compositions useful as degraders of mk2 kinase.
The present disclosure provides co... |
|
2023
|
Invention
|
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and met... |
|
|
Invention
|
Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2... |
|
|
Invention
|
Substituted imidazopyrazine compounds as ligand directed degraders of irak3.
Provided herein are... |
|
|
Invention
|
Compounds for the treatment of neurodegenerative diseases.
Provided herein are compounds and com... |
|
|
Invention
|
Heterocyclic pad4 inhibitors.
The disclosure generally relates to 3,5,6,7-tetrahydro-8H-imidazo[... |
|
|
Invention
|
Heterocyclic pad4 inhibitors.
The disclosure generally relates to compounds of Formula I, compri... |
|
|
Invention
|
Method for predicting response to a t cell therapy.
The present disclosure relates to methods fo... |
|
|
Invention
|
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior ther... |
|
|
Invention
|
Methods and uses related to t cell therapy and production of same.
Provided herein are uses of T... |
|
|
Invention
|
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma.
Pro... |
|
|
Invention
|
Methods of treating tumor.
The disclosure provides a method for treating a subject afflicted wit... |
|
2022
|
Invention
|
Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases.
Pr... |
|
|
Invention
|
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma.
P... |
|
|
Invention
|
Modulators of camkk2 as ligand directed degraders.
Provided herein are compounds of formula (I) ... |
|
|
Invention
|
Process for preparing histone demethylase inhibitors.
Provided herein are methods for preparing ... |
|
|
Invention
|
T cell therapy in patients who have had prior stem cell transplant.
Provided herein are uses of ... |
|
|
Invention
|
Treatment of cancer with kdm4 inhibitors.
Provided herein are compositions and methods for the t... |
|
2021
|
Invention
|
Actriib ligand trap compositions and uses thereof. The present application relates to recombinant... |
